The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
BACKGROUND
Although intravenous iron (IVI) is thought to have potential inflammatory and atherogenic effects, there are not enough studies comparing these effects in chronic hemodialysis (HD) patients. In this study, different doses and types of IVI were examined for effects on inflammation and oxidative stress.


METHODS
Chronic HD patients (n=101) were grouped into those not receiving IVI (group 1, n=29), those getting intermittent iron sucrose (group 2, n=25), those receiving intermittent iron dextran (group 3, n=24) and those getting a once monthly total dose of iron dextran (group 4, n=23). Malondialdehyde (MDA), advanced oxidation protein product (AOPP), C-reactive protein (CRP) and TNF-α levels were measured on days 0, 2, 7 and 28.


RESULTS
Groups were similar regarding age, sex, hemoglobin, iron indices and total amount of IVI given monthly. Although MDA levels at days 7 and 28, AOPP levels at days 0 and 28, CRP levels at day 28 and TNF-α level at day 7 were higher than at other days, there were no significant differences between the IVI groups on statistical analysis.


CONCLUSIONS
The different types and doses (intermittent or once monthly total dose) of IVI treatments are well tolerated without negative effects on the markers of lipid and protein oxidation and inflammatory indices in chronic HD patients.
Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey.
Abdulbaki
A
Kumbasar
Meltem
M
Gursu
Cagdas
C
Kaya
Savas
S
Ozturk
Abdulkadir
A
Ergen
Ahu
A
Kemik
Zeki
Z
Aydin
Sami
S
Uzun
Serhat
S
Karadag
Rumeyza
R
Kazancioglu
D000328:Adult; D062107:Advanced Oxidation Protein Products / Q000097:blood; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004334:Drug Administration Schedule; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid / Q000008:administration & dosage* / Q000009:adverse effects; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000276:immunology*; D018836:Inflammation Mediators / Q000097:blood; D007262:Infusions, Intravenous; D007501:Iron / Q000097:blood; D007505:Iron-Dextran Complex / Q000008:administration & dosage* / Q000009:adverse effects; D007674:Kidney Diseases / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D006435:Renal Dialysis; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D062107:Advanced Oxidation Protein Products; D015415:Biomarkers; D005290:Ferric Compounds; D006397:Hematinics; D018836:Inflammation Mediators; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D007505:Iron-Dextran Complex; D002097:C-Reactive Protein; D007501:Iron; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid